Press coverage about Pulse Biosciences (NASDAQ:PLSE) has been trending somewhat positive recently, Accern reports. The research firm identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Pulse Biosciences earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.2873371976334 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s rankings:
- Pulse Biosciences Announces Withdrawal and Planned Resubmission of 510(k) Application for the PulseTx TM System (enhancedonlinenews.com)
- Mid-Day Market Update: Dow Up 1%; Achillion Pharmaceuticals Shares Plunge (benzinga.com)
- Bloomberg Markets: Dave Wilson’s Stock of the Day for Sept. 11 (bloomberg.com)
- Oversold Conditions For Pulse Biosciences (PLSE) (thestreet.com)
- PULSE BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K) (4-traders.com)
Pulse Biosciences (PLSE) traded down 10.80% during mid-day trading on Tuesday, reaching $13.79. 354,835 shares of the company’s stock were exchanged. Pulse Biosciences has a 52 week low of $5.20 and a 52 week high of $39.50. The company’s 50 day moving average price is $22.27 and its 200-day moving average price is $25.33. The company’s market capitalization is $197.67 million.
Pulse Biosciences (NASDAQ:PLSE) last released its earnings results on Thursday, July 27th. The company reported ($0.43) EPS for the quarter.
In other news, Director Maky Zanganeh acquired 8,290 shares of Pulse Biosciences stock in a transaction that occurred on Wednesday, August 2nd. The shares were purchased at an average cost of $25.15 per share, for a total transaction of $208,493.50. Following the completion of the purchase, the director now directly owns 287,225 shares of the company’s stock, valued at approximately $7,223,708.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Robert W. Duggan acquired 277,450 shares of Pulse Biosciences stock in a transaction that occurred on Thursday, August 3rd. The shares were purchased at an average price of $23.14 per share, for a total transaction of $6,420,193.00. Following the completion of the purchase, the insider now directly owns 3,153,234 shares of the company’s stock, valued at $72,965,834.76. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 314,530 shares of company stock valued at $7,318,495. Company insiders own 6.70% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Pulse Biosciences (PLSE) Receives Media Sentiment Rating of 0.10” was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://sportsperspectives.com/2017/09/12/pulse-biosciences-plse-receives-media-sentiment-rating-of-0-10.html.
About Pulse Biosciences
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.
Receive News & Ratings for Pulse Biosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.